PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Results of Operations and Financial Condition

Item2.02

On March1, 2017, Puma Biotechnology, Inc. issued a press release
announcing its financial results for the fourth quarter and
fiscal year ended December31, 2016. A copy of the press release
is furnished herewith as Exhibit 99.1 and is incorporated by
reference herein.

The information in this Item 2.02, including the accompanying
exhibit, is being furnished and shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section. The information in this Item 2.02
shall not be incorporated by reference into any filing to the
Securities Act of 1933, as amended, or the Exchange Act,
regardless of any general incorporation language in such filing.

About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Recent Trading Information

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) closed its last trading session up +1.35 at 38.05 with 647,610 shares trading hands.